Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

unknown267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

NCT04588064
unknownnot_applicable

Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01)

NCT05574907
unknownnot_applicable

Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer

NCT04778345

Clinical Trials (3)

Showing 3 of 3 trials
NCT04588064Not Applicable

18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma

Completed
NCT05574907Not Applicable

Characterizing Breast Cancer With 68Ga-FAPI PET/CT (PFB-01)

Unknown
NCT04778345Not Applicable

Preoperative Abdominal Enhanced CT, 18F-FDG PET/CT and 68Ga-FAPI PET/CT in Peritoneal Carcinomatosis of Gastric Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
3